FCRLB-mediated dual control of tumor metabolism and macrophage polarization promotes lung cancer malignancy
Preprint
- 31 October 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Anti–PD-1 therapy has improved outcomes in non-small cell lung cancer (NSCLC), yet primary and acquired resistance remain common. Pinpointing regulators of tumor–immune crosstalk is therefore critical to enhance therapeutic efficacy. Methods We integrated multi-omics sequencing with ensemble machine-learning to nominate prognostic genes in NSCLC, followed by pathway and intercellular-signaling analyses (pseudotime analysis, GSVA, and functional enrichment). We generated shRNA-mediated FCRLB-knockdown NSCLC cell lines and performed molecular and immunological assays. A murine lung-cancer xenograft model was used to validate the role of the candidate gene in tumor progression and its impact on the tumor microenvironment (TME). Results We identified FCRLB as a key gene influencing lung cancer prognosis via transcriptomic gene screening, and elucidated its unique roles in tumor cells and macrophages. FCRLB-highly expressing tumor cells exhibited high activation of the PI3K signaling and reactive oxygen species (ROS) pathways, regulated metabolic pathways such as pyridine metabolism and terpenoid quinone biosynthesis, and induced C-C motif chemokine ligand 2 (CCL2) production. Additionally, high FCRLB expression in monocyte-derived macrophages (mo-Macs) promoted M2-like polarization, thereby further exacerbating lung cancer malignancy. Conclusions Our data identify and functionally validate FCRLB as a pro-tumor regulator in NSCLC.FCRLB regulates the secretion of multiple cytokines (including CCL2) by tumor cells via the ROS pathway and PI3K signaling pathway, thereby promoting M2 polarization of macrophages. Additionally, FCRLB exerts a positive regulatory effect on the malignant progression of NSCLC. This finding provides a potential novel target for overcoming immunotherapys resistance in NSCLC.Keywords
All Related Versions
- Version 1, 2025-10-31, Research Square
- Published version: Journal of Translational Medicine, 24 (1).
This publication has 31 references indexed in Scilit:
- OPG promotes lung metastasis by reducing CXCL10 production of monocyte-derived macrophages and decreasing NK cell recruitmentEBioMedicine, 2024
- New promises and challenges in the treatment of advanced non-small-cell lung cancerThe Lancet, 2024
- Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunityNature Nanotechnology, 2024
- Advances and challenges in the treatment of lung cancerBiomedicine & Pharmacotherapy, 2023
- SLC7A5 is a lung adenocarcinoma-specific prognostic biomarker and participates in forming immunosuppressive tumor microenvironmentHeliyon, 2022
- Integrated microbiome, metabolome, and proteome analysis identifies a novel interplay among commensal bacteria, metabolites and candidate targets in non‐small cell lung cancerClinical and Translational Medicine, 2022
- Exosomal microRNAs induce tumor-associated macrophages via PPARγ during tumor progression in SHH medulloblastomaCancer Letters, 2022
- Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation statusBlood Cancer Journal, 2019
- Aryl Hydrocarbon Receptor Controls Monocyte Differentiation into Dendritic Cells versus MacrophagesImmunity, 2017
- Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progressionCancer Letters, 2017